-DOCSTART- -X- O
To -X- _ O
better -X- _ O
understand -X- _ O
the -X- _ O
systemic -X- _ O
response -X- _ O
to -X- _ O
naturally -X- _ B-Patient
acquired -X- _ I-Patient
acute -X- _ I-Patient
respiratory -X- _ I-Patient
viral -X- _ I-Patient
infections -X- _ I-Patient
, -X- _ O
we -X- _ O
prospectively -X- _ O
enrolled -X- _ O
1610 -X- _ O
healthy -X- _ O
adults -X- _ O
in -X- _ O
2009 -X- _ O
and -X- _ O
2010. -X- _ O
Of -X- _ O
these -X- _ O
, -X- _ O
142 -X- _ B-Patient
subjects -X- _ I-Patient
were -X- _ O
followed -X- _ O
for -X- _ O
detailed -X- _ O
evaluation -X- _ O
of -X- _ O
acute -X- _ O
viral -X- _ O
respiratory -X- _ O
illness. -X- _ O
We -X- _ O
examined -X- _ O
peripheral -X- _ O
blood -X- _ O
gene -X- _ O
expression -X- _ O
at -X- _ O
7 -X- _ O
timepoints -X- _ O
: -X- _ O
enrollment -X- _ O
, -X- _ O
5 -X- _ O
illness -X- _ O
visits -X- _ O
and -X- _ O
the -X- _ O
end -X- _ O
of -X- _ O
each -X- _ O
year -X- _ O
of -X- _ O
the -X- _ O
study. -X- _ O
133 -X- _ O
completed -X- _ O
all -X- _ O
study -X- _ O
visits -X- _ O
and -X- _ O
yielded -X- _ O
technically -X- _ O
adequate -X- _ O
peripheral -X- _ O
blood -X- _ O
microarray -X- _ O
gene -X- _ O
expression -X- _ O
data. -X- _ O
Seventy-three -X- _ B-Outcome
( -X- _ I-Outcome
55 -X- _ I-Outcome
% -X- _ I-Outcome
) -X- _ I-Outcome
had -X- _ I-Outcome
an -X- _ I-Outcome
influenza -X- _ I-Outcome
virus -X- _ I-Outcome
infection -X- _ I-Outcome
, -X- _ I-Outcome
64 -X- _ I-Outcome
influenza -X- _ I-Outcome
A -X- _ I-Outcome
and -X- _ I-Outcome
9 -X- _ I-Outcome
influenza -X- _ I-Outcome
B. -X- _ I-Outcome
The -X- _ I-Outcome
remaining -X- _ I-Outcome
subjects -X- _ I-Outcome
had -X- _ I-Outcome
a -X- _ I-Outcome
rhinovirus -X- _ I-Outcome
infection -X- _ I-Outcome
( -X- _ I-Outcome
N -X- _ I-Outcome
= -X- _ I-Outcome
32 -X- _ I-Outcome
) -X- _ I-Outcome
, -X- _ I-Outcome
other -X- _ I-Outcome
viral -X- _ I-Outcome
infections -X- _ I-Outcome
( -X- _ I-Outcome
N -X- _ I-Outcome
= -X- _ I-Outcome
4 -X- _ I-Outcome
) -X- _ I-Outcome
, -X- _ I-Outcome
or -X- _ I-Outcome
no -X- _ I-Outcome
viral -X- _ I-Outcome
agent -X- _ I-Outcome
identified -X- _ I-Outcome
( -X- _ I-Outcome
N -X- _ I-Outcome
= -X- _ I-Outcome
24 -X- _ I-Outcome
) -X- _ I-Outcome
. -X- _ I-Outcome
The -X- _ I-Outcome
results -X- _ I-Outcome
, -X- _ I-Outcome
which -X- _ I-Outcome
were -X- _ I-Outcome
replicated -X- _ I-Outcome
between -X- _ I-Outcome
two -X- _ I-Outcome
seasons -X- _ I-Outcome
, -X- _ I-Outcome
showed -X- _ I-Outcome
a -X- _ I-Outcome
dramatic -X- _ I-Outcome
upregulation -X- _ I-Outcome
of -X- _ I-Outcome
interferon -X- _ I-Outcome
pathway -X- _ I-Outcome
and -X- _ I-Outcome
innate -X- _ I-Outcome
immunity -X- _ I-Outcome
genes. -X- _ I-Outcome
This -X- _ I-Outcome
persisted -X- _ I-Outcome
for -X- _ I-Outcome
2-4 -X- _ I-Outcome
days. -X- _ I-Outcome
The -X- _ I-Outcome
data -X- _ I-Outcome
show -X- _ I-Outcome
a -X- _ I-Outcome
recovery -X- _ I-Outcome
phase -X- _ I-Outcome
at -X- _ I-Outcome
days -X- _ I-Outcome
4 -X- _ I-Outcome
and -X- _ I-Outcome
6 -X- _ I-Outcome
with -X- _ I-Outcome
differentially -X- _ I-Outcome
expressed -X- _ I-Outcome
transcripts -X- _ I-Outcome
implicated -X- _ I-Outcome
in -X- _ I-Outcome
cell -X- _ I-Outcome
proliferation -X- _ I-Outcome
and -X- _ I-Outcome
repair. -X- _ I-Outcome
By -X- _ I-Outcome
day -X- _ I-Outcome
21 -X- _ I-Outcome
the -X- _ I-Outcome
gene -X- _ I-Outcome
expression -X- _ I-Outcome
pattern -X- _ I-Outcome
was -X- _ I-Outcome
indistinguishable -X- _ I-Outcome
from -X- _ I-Outcome
baseline -X- _ I-Outcome
( -X- _ I-Outcome
enrollment -X- _ I-Outcome
) -X- _ I-Outcome
. -X- _ I-Outcome
Influenza -X- _ I-Outcome
virus -X- _ I-Outcome
infection -X- _ I-Outcome
induced -X- _ I-Outcome
a -X- _ I-Outcome
higher -X- _ I-Outcome
magnitude -X- _ I-Outcome
and -X- _ I-Outcome
longer -X- _ I-Outcome
duration -X- _ I-Outcome
of -X- _ I-Outcome
the -X- _ I-Outcome
shared -X- _ I-Outcome
expression -X- _ I-Outcome
signature -X- _ I-Outcome
of -X- _ I-Outcome
illness -X- _ I-Outcome
compared -X- _ I-Outcome
to -X- _ I-Outcome
the -X- _ I-Outcome
other -X- _ I-Outcome
viral -X- _ I-Outcome
infections. -X- _ I-Outcome
Using -X- _ I-Outcome
lineage -X- _ I-Outcome
and -X- _ I-Outcome
activation -X- _ I-Outcome
state-specific -X- _ I-Outcome
transcripts -X- _ I-Outcome
to -X- _ I-Outcome
produce -X- _ I-Outcome
cell -X- _ I-Outcome
composition -X- _ I-Outcome
scores -X- _ I-Outcome
, -X- _ I-Outcome
patterns -X- _ I-Outcome
of -X- _ I-Outcome
B -X- _ I-Outcome
and -X- _ I-Outcome
T -X- _ I-Outcome
lymphocyte -X- _ I-Outcome
depressions -X- _ I-Outcome
accompanied -X- _ I-Outcome
by -X- _ I-Outcome
a -X- _ I-Outcome
major -X- _ I-Outcome
activation -X- _ I-Outcome
of -X- _ I-Outcome
NK -X- _ I-Outcome
cells -X- _ I-Outcome
were -X- _ I-Outcome
detected -X- _ I-Outcome
in -X- _ I-Outcome
the -X- _ I-Outcome
acute -X- _ I-Outcome
phase -X- _ I-Outcome
of -X- _ I-Outcome
illness. -X- _ I-Outcome
The -X- _ O
data -X- _ O
also -X- _ O
demonstrate -X- _ O
multiple -X- _ O
dynamic -X- _ O
gene -X- _ O
modules -X- _ O
that -X- _ O
are -X- _ O
reorganized -X- _ O
and -X- _ O
strengthened -X- _ O
following -X- _ O
infection. -X- _ O
Finally -X- _ O
, -X- _ O
we -X- _ O
examined -X- _ O
pre- -X- _ O
and -X- _ O
post-infection -X- _ O
anti-influenza -X- _ O
antibody -X- _ O
titers -X- _ O
defining -X- _ O
novel -X- _ O
gene -X- _ O
expression -X- _ O
correlates -X- _ O
. -X- _ O

